| Identification | Back Directory | [Name]
Tanogitran | [CAS]
637328-69-9 | [Synonyms]
BIBT986
BIBT-986
BIBT 986
Tanogitran
Tanogitran USP/EP/BP
MAOALPSHCIBFJZ-RUZDIDTESA-N
N-[(1R)-1-[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]glycine
Glycine, N-[(1R)-1-[2-[[[4-(aMinoiMinoMethyl)phenyl]aMino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]-1-Methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]- | [Molecular Formula]
C25H31N7O3 | [MDL Number]
MFCD18206857 | [MOL File]
637328-69-9.mol | [Molecular Weight]
477.56 |
| Hazard Information | Back Directory | [Uses]
Tanogitran is a dual inhibitor targeting Factor Xa and thrombin (thrombin), with Ki values of 26 and 2.7 nM, respectively. Tanogitran exhibits anticoagulant activity and can be used for research in thrombotic diseases[1][2]. | [References]
[1] Gómez-Outes A, et al. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis. 2011 Feb;5(1):33-59. DOI:10.1177/1753944710387808
[2] Remko M, et al. Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors. Molecules. 2016 Feb 4;21(2):185. DOI:10.3390/molecules21020185 |
|
|